Redesign Science

About Redesign Science

Redesign Science, Inc. operates as a computational drug discovery company, positioning itself at the intersection of physics, computer science, and biotechnology. Founded in 2017 by David Rooklin and Haotian Li, the New York-based firm aims to address the challenges of early-stage drug discovery for complex disease targets. The founders' journey began during their time at New York University, where they spent a decade collaborating on computational chemistry approaches. Rooklin, the CEO, holds a Ph.D. in computational biology from NYU and invented AlphaSpace, a method for identifying druggability in difficult targets. Li, the CTO, brings expertise in scaling the company's computational infrastructure and core algorithms.

The company's core business revolves around its proprietary technology platform, NUVO™, which integrates physics-based molecular dynamics simulations with generative AI. This platform simulates the dynamic motion of proteins to uncover novel drug sites that are often invisible to traditional, static structural analysis methods. By analyzing the complex equilibria of protein systems, Redesign Science can identify druggable opportunities within targets previously considered undruggable, particularly for diseases like cancer and inflammatory bowel disease. The business model is centered on strategic co-development partnerships with biotechnology and pharmaceutical companies. Through these milestone-driven collaborations, the company provides its partners with novel chemical matter and helps unlock the potential of less-understood targets, reducing the time and investment in early-stage discovery. Additionally, Redesign Science is developing its own internal pipeline of small molecule therapeutics.

The firm has secured significant financial backing to fuel its growth and technological development. It raised $2 million in a seed round in 2019, led by Notation Capital. This was followed by a total of $15 million in Seed-2 and Seed-3 financings in 2021, led by Collaborative Fund and Kaitai Capital, respectively, bringing its total funding to $17 million. These funds are allocated towards expanding its cloud computing infrastructure, advancing its screening algorithms, and progressing both its partnership programs and internal pipeline.